4,262 Shares of Danaher Corporation $DHR Acquired by Patriot Investment Management Group Inc.

Patriot Investment Management Group Inc. purchased a new position in Danaher Corporation (NYSE:DHR) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,262 shares of the conglomerate’s stock, valued at approximately $944,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NFSG Corp raised its holdings in shares of Danaher by 488.8% during the third quarter. NFSG Corp now owns 3,091 shares of the conglomerate’s stock worth $685,000 after purchasing an additional 2,566 shares during the period. Detalus Advisors LLC boosted its holdings in shares of Danaher by 975.1% in the 3rd quarter. Detalus Advisors LLC now owns 12,708 shares of the conglomerate’s stock valued at $2,815,000 after buying an additional 11,526 shares during the period. Murphy Middleton Hinkle & Parker Inc. acquired a new position in shares of Danaher in the 3rd quarter valued at about $6,985,000. Walser Wealth Management Company A Ltd Liability Co acquired a new position in shares of Danaher in the 3rd quarter valued at about $1,459,000. Finally, V Square Quantitative Management LLC grew its position in shares of Danaher by 6.9% during the 3rd quarter. V Square Quantitative Management LLC now owns 13,696 shares of the conglomerate’s stock valued at $3,034,000 after buying an additional 884 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analysts Set New Price Targets

Several equities research analysts recently weighed in on DHR shares. Royal Bank Of Canada increased their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. UBS Group assumed coverage on Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price for the company. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. The Goldman Sachs Group upped their target price on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Finally, Morgan Stanley increased their price target on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Stock Performance

DHR stock opened at $231.52 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock’s fifty day moving average is $213.55 and its two-hundred day moving average is $195.74.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the company posted $0.77 earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, research analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.